Unresectable Stage III or Stage IV Melanoma
Oncology
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Celldex TherapeuticsHAMPTON, NJ
2 programs2
CR011-vcMMAEPhase 1/21 trial
Combination of varlilumab and ipilimumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Celldex TherapeuticsCombination of varlilumab and ipilimumab
Celldex TherapeuticsCR011-vcMMAE
Clinical Trials (2)
Total enrollment: 126 patients across 2 trials
A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Start: Apr 2015Est. completion: Nov 20169 patients
Phase 1/2Terminated
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
Start: Jun 2006Est. completion: May 2011117 patients
Phase 1/2Completed
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
6m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
6m ago
Office Administrator
SystImmune
7m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
17m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
20m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
20m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space